I don't know the timing.
Regarding the FDA this is where it goes beyond my knowledge. For the PNH orphan indication RVX is using the RVX-208 molecule which is also being used in the BOM trial. I do not understand the regulatory considerations when trials are being conducted with the same drug but for different indications.